Entering text into the input field will update the search result below

Intercept Pharma reports Q4 and FY15 results

  • Intercept Pharmaceuticals (NASDAQ:ICPT -0.2%) Q4 results: Revenues: $0.4M (+0.4%); R&D Expense: $44.4M (+87.3%); SG&A: $44.9M (+277.3%); Net Loss: ($88.3M) (-153.7%); Loss Per Share: ($3.62) (-122.1%).
  • FY2015 results: Revenues: $2.8M (+64.7%); R&D Expense: $128.2M (+59.7%); SG&A: $103.7M (+199.7%); Net Loss: ($226.4M) (+20.1%); Loss Per Share: ($9.56) (+29.9%); Quick Assets: $628.1M (+162.0%).
  • 2016 Guidance: Adjusted Operating Expenses: $360M - 400M.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
ICPT--
Intercept Pharmaceuticals, Inc.